---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T10:39:14.975068'
end_time: '2025-12-27T10:43:55.135027'
duration_seconds: 280.16
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: KCTD14
  gene_symbol: KCTD14
  uniprot_accession: Q9BQ13
  protein_description: 'RecName: Full=BTB/POZ domain-containing protein KCTD14;'
  gene_info: Name=KCTD14;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB.
    (IPR003131); BTB_2 (PF02214)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 10
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BQ13
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD14;
- **Gene Information:** Name=KCTD14;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD14" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD14' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD14** (gene ID: KCTD14, UniProt: Q9BQ13) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BQ13
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD14;
- **Gene Information:** Name=KCTD14;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD14" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD14' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD14** (gene ID: KCTD14, UniProt: Q9BQ13) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and scope
We verified the target gene/protein identity, then synthesized current structural and functional understanding for human KCTD14, prioritizing 2023–2024 sources and authoritative family-wide studies where KCTD14-specific data are scarce. We emphasize definitional concepts, recent developments, applications, expert viewpoints, and quantitative data, citing primary literature and reviews.

Identity verification and canonical features
• Gene/protein identity: The requested target is human KCTD14, UniProt Q9BQ13, a BTB/POZ domain–containing protein in Homo sapiens. KCTD proteins are defined by an N‑terminal BTB/POZ (also called T1-type BTB) domain that mediates oligomerization and, in many family members, recruitment of Cullin3 (Cul3) to form CRL3 E3 ubiquitin ligase complexes (structural overview) (balasco2024acomprehensiveanalysis pages 1-2).
• Domains: Family-level analyses consistently place KCTD proteins within the BTB/POZ superfamily; the BTB fold is described as a β-sheet flanked by five α-helices. The defining BTB domain can both promote oligomerization and interact with partners, most notably Cul3; C-terminal regions are variable and implicated in substrate recognition (balasco2024acomprehensiveanalysis pages 1-2).
• Oligomeric organization: KCTD BTB domains frequently assemble into pentamers. AlphaFold-based structural surveys support widespread pentameric assemblies across the family; however, exact oligomeric arrangements can vary by member (balasco2024acomprehensiveanalysis pages 1-2).

Key concepts and definitions
• KCTD family and CRL3 adaptors: Many KCTD proteins function as substrate adaptors for Cul3-based E3 ubiquitin ligases via their N-terminal BTB/POZ domains. The C-terminal domains provide substrate-selection interfaces. Not all KCTDs bind Cul3; recognizable structural and sequence features in BTB subregions differentiate binders from non-binders (balasco2024acomprehensiveanalysis pages 1-2).
• Quantitative scope: A 2024 comprehensive AlphaFold modeling study generated KCTD–Cul3 complex models for the entire family and obtained reliable/stable models only for the subset of KCTDs that are experimentally known to interact with Cul3 (15 family members), indicating discriminatory power and family partitioning into Cul3-binders and non-binders (balasco2024acomprehensiveanalysis pages 1-2).

Recent developments and latest research (prioritize 2023–2024)
• AF-based Cul3 recognition map (2024): Balasco et al. systematically modeled the BTB segments of human KCTD proteins against Cul3 (residues 17–134). The study reports for KCTD14 (BTB T33–D124) that no stable Cul3 complex was detected in the 5:5 assembly prediction, in contrast to several other KCTDs, including KCTD7, that formed stable predicted complexes and have experimental structures (KCTD7–Cul3 cryo-EM used as validation) (International Journal of Molecular Sciences, 2024-02; https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).
• Family-level structural determinants (2024): The same analysis highlights clear structural differences in BTB domains between Cul3-binding and non-binding KCTDs, and supports the view that BTB-encoded features—rather than family membership alone—determine Cul3 engagement (balasco2024acomprehensiveanalysis pages 1-2).
• AF-based structural relationships (2021): AlphaFold-derived pseudo-phylogenetic analysis reported a specific structural pairing of KCTD7 with KCTD14, suggesting related C‑terminal folds despite low sequence identity, and supporting the presence of shared architectural principles within this clade. The study also delineated family subgroups that do and do not bind Cul3, underscoring that membership in a structural cluster does not by itself guarantee Cul3 binding (Biomolecules, 2021-12; https://doi.org/10.3390/biom11121862) (esposito2021alphafoldpredictedstructuresof pages 10-12).

Current functional understanding of human KCTD14
• Primary biochemical role: No direct enzymatic or substrate-transport activity has been assigned to KCTD14. By family analogy, KCTDs are either (a) Cul3 adaptors that recruit substrates for ubiquitination via their C-termini, or (b) BTB-scaffolded oligomers that act in other protein–protein interaction networks without Cul3. For KCTD14, AF-based modeling found no stable Cul3 binding, arguing against a canonical CRL3 adaptor role, at least via the tested BTB segment and the standard 5:5 assembly (balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).
• Oligomerization: KCTD14 is expected to oligomerize via its BTB domain, most commonly as a homopentamer, in keeping with the family trend; AlphaFold family analyses support pentamerization as a prevalent architecture (balasco2024acomprehensiveanalysis pages 1-2). AlphaFold-derived structural relationships place KCTD14 near KCTD7, indicating a related domain organization, although this does not infer shared Cul3 binding (esposito2021alphafoldpredictedstructuresof pages 10-12).
• Cellular localization: Direct experimental localization for KCTD14 remains sparse. Family-level syntheses indicate KCTD proteins typically localize to cytoplasm, with documented instances in mitochondria and nucleus depending on member and context; these statements are family-level and not KCTD14-specific (lobato2025substrateidentificationanda pages 11-16, vergara2025substrateidentificationandb pages 11-16).

Pathways and interactors
• Cul3 interaction status: The 2024 AF survey explicitly reports “no stable complex detected” for KCTD14–Cul3 under a 5:5 symmetry assumption for the BTB–Cul3 assembly, contrasting with confirmed binders such as KCTD7 (used as an internal validation of the AF approach). This suggests KCTD14 may not be a canonical Cul3 adaptor or may require additional regions/contexts for interaction that are not captured by the BTB-only modeling (balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).
• Family signaling paradigms relevant to inference: KCTD adaptors that do bind Cul3 participate in ubiquitin-mediated regulation across signaling pathways; non-binding KCTDs can engage other partners (e.g., GABAB2 or transcription factors) through their CTDs. Given AF evidence of non-binding for KCTD14’s BTB, functional hypotheses should prioritize non-Cul3 scaffolding roles pending direct experiments (balasco2024acomprehensiveanalysis pages 1-2).

Disease associations and translational context
• Family context: Multiple KCTD members are implicated in cancer and neurological disease; the 2024 structural survey motivates target-specific modulation strategies that hinge on whether a KCTD binds Cul3. These family-level observations support the need to clarify KCTD14’s adaptor status before considering therapeutic strategies (balasco2024acomprehensiveanalysis pages 1-2).
• KCTD14-specific disease evidence: We did not find direct KCTD14 disease mechanisms in the curated, cited sources. As of the 2024 AF analysis, KCTD14 is grouped structurally with KCTD7 but distinguished by predicted lack of Cul3 binding; caution is warranted in extrapolating disease roles from KCTD7 or other family members (esposito2021alphafoldpredictedstructuresof pages 10-12, balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).

Expert opinions and analysis from authoritative sources
• Structural experts (2024): Comprehensive AF modeling indicates that only a subset of KCTDs yield stable, plausible BTB–Cul3 complexes; the remainder—including KCTD14—likely serve alternative roles. The authors argue that accurate three-dimensional models for KCTD–Cul3 interactions can guide compound design, but only for Cul3-binding members (balasco2024acomprehensiveanalysis pages 1-2, balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).
• Structural relationship caution (2021): Despite KCTD14 clustering with KCTD7 in AlphaFold-based similarity, AF-derived relationships do not substitute for biochemical validation; detailed oligomeric state and partner engagement require experimentation (esposito2021alphafoldpredictedstructuresof pages 10-12).

Relevant statistics and data from recent studies
• Family size and Cul3 binding: The 2024 analysis reports reliable modeling of KCTD–Cul3 complexes for the 15 family members known to interact with Cul3, and explicit non-binding predictions for others, including KCTD14 (balasco2024acomprehensiveanalysis pages 1-2, balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).
• KCTD14–Cul3 prediction: BTB fragment used for KCTD14 modeling T33–D124; predicted “no stable complex” in the C5‑symmetric 5:5 KCTD14BTB–Cul3 assembly (balasco2024acomprehensiveanalysis pages 2-4).

Applications and real-world implementations
• Target selection for degrader design and E3-modulation: For KCTD family members that bind Cul3, structural models enable rational targeting of substrate recognition or BTB–Cul3 interfaces; for non-binders like KCTD14 (per AF prediction), therapeutic concepts should instead explore CTD-mediated scaffolding interactions or hetero-oligomeric assemblies independent of Cul3 (balasco2024acomprehensiveanalysis pages 1-2, balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).

Limitations and open questions
• Sparse, KCTD14-specific data: Peer-reviewed experimental studies directly assigning function, cellular localization, substrates, or interactors to human KCTD14 are limited in the curated sources used here. The most specific recent insight is the AF-based negative prediction for Cul3 binding (balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4).
• Next experimental steps: Verify oligomeric state and stability of full-length KCTD14; test Cul3 interaction with full-length protein and/or alternative stoichiometries; map CTD interactions via proteomics; determine subcellular localization using tagged constructs and antibodies.

Summary conclusion
Human KCTD14 (Q9BQ13) is a BTB/POZ-domain protein of the KCTD family with predicted pentamerizing capacity via its BTB domain and a structurally variable C-terminus. Recent AlphaFold-based work (2024) indicates KCTD14’s BTB domain does not form a stable 5:5 complex with Cullin3, distinguishing it from canonical CRL3 adaptors such as KCTD7 and arguing that KCTD14’s primary function may not be as a Cul3 adaptor. AlphaFold structural relationships place KCTD14 close to KCTD7 at the level of fold similarity, but this does not override the Cul3 non-binding prediction. Direct functional, localization, and disease-link data specific to KCTD14 remain sparse; therefore, current understanding relies on high-confidence family-level principles and a 2024 negative prediction for Cul3 binding, prioritizing experimental validation to define KCTD14’s partners and pathways (balasco2024acomprehensiveanalysis pages 1-2, balasco2024acomprehensiveanalysis pages 4-5, balasco2024acomprehensiveanalysis pages 2-4, esposito2021alphafoldpredictedstructuresof pages 10-12, lobato2025substrateidentificationanda pages 11-16, vergara2025substrateidentificationandb pages 11-16).

References

1. (balasco2024acomprehensiveanalysis pages 1-2): Nicole Balasco, Luciana Esposito, Giovanni Smaldone, Marco Salvatore, and Luigi Vitagliano. A comprehensive analysis of the structural recognition between kctd proteins and cullin 3. International Journal of Molecular Sciences, 25:1881, Feb 2024. URL: https://doi.org/10.3390/ijms25031881, doi:10.3390/ijms25031881. This article has 12 citations and is from a poor quality or predatory journal.

2. (balasco2024acomprehensiveanalysis pages 4-5): Nicole Balasco, Luciana Esposito, Giovanni Smaldone, Marco Salvatore, and Luigi Vitagliano. A comprehensive analysis of the structural recognition between kctd proteins and cullin 3. International Journal of Molecular Sciences, 25:1881, Feb 2024. URL: https://doi.org/10.3390/ijms25031881, doi:10.3390/ijms25031881. This article has 12 citations and is from a poor quality or predatory journal.

3. (balasco2024acomprehensiveanalysis pages 2-4): Nicole Balasco, Luciana Esposito, Giovanni Smaldone, Marco Salvatore, and Luigi Vitagliano. A comprehensive analysis of the structural recognition between kctd proteins and cullin 3. International Journal of Molecular Sciences, 25:1881, Feb 2024. URL: https://doi.org/10.3390/ijms25031881, doi:10.3390/ijms25031881. This article has 12 citations and is from a poor quality or predatory journal.

4. (esposito2021alphafoldpredictedstructuresof pages 10-12): Luciana Esposito, Nicole Balasco, Giovanni Smaldone, Rita Berisio, Alessia Ruggiero, and Luigi Vitagliano. Alphafold-predicted structures of kctd proteins unravel previously undetected relationships among the members of the family. Biomolecules, 11:1862, Dec 2021. URL: https://doi.org/10.3390/biom11121862, doi:10.3390/biom11121862. This article has 31 citations and is from a poor quality or predatory journal.

5. (lobato2025substrateidentificationanda pages 11-16): R Lobato. Substrate identification and structural characterization of the kctd9/cullin3 ubiquitin ligase complex. Unknown journal, 2025.

6. (vergara2025substrateidentificationandb pages 11-16): R Lobato Vergara. Substrate identification and structural characterization of the kctd9/cullin3 ubiquitin ligase complex. Unknown journal, 2025.

## Citations

1. balasco2024acomprehensiveanalysis pages 1-2
2. esposito2021alphafoldpredictedstructuresof pages 10-12
3. balasco2024acomprehensiveanalysis pages 2-4
4. balasco2024acomprehensiveanalysis pages 4-5
5. lobato2025substrateidentificationanda pages 11-16
6. vergara2025substrateidentificationandb pages 11-16
7. https://doi.org/10.3390/ijms25031881
8. https://doi.org/10.3390/biom11121862
9. https://doi.org/10.3390/ijms25031881,
10. https://doi.org/10.3390/biom11121862,